Matching-adjusted indirect treatment comparison of [¹⁷⁷Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [¹⁷⁷Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours.

ABSTRACT: Head-to-head comparisons of the efficacy of treatments for gastroenteropancreatic neuroendocrine tumours (GEP-NETs) have not yet been reported. This study used a series of matching-adjusted indirect comparisons to indirectly compare the effectiveness of [¹⁷⁷Lu]Lu-DOTA-TATE to everolimus, sunitinib and best supportive care (BSC) for extending progression-free survival and overall survival in patients with advanced, unresectable gastrointestinal (GI)-NETs and P-NETs. The results of the main analysis suggest that after accounting for differences in key prognostic variables, the hazard of progression was 62% (hazard ratio [HR], 0.38; confidence interval [CI]₉₅ 0.25-0.58) and 65% (HR 0.35 CI₉₅ 0.21-0.59) lower in patients with GI-NETs treated with [¹⁷⁷

SUBMITTER: Khan MS 

PROVIDER: S-EPMC8591206 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature